PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Torres, Roarelis
ED  - Wolfgang, Curt
ED  - Weiden, Peter J
ED  - Hamilton, Jennifer
ED  - Stahl, Stephan M
ED  - Lauriello, John
TI  - Iloperidone for the Treatment of Schizophrenia—Selected Posters
DP  - 2008 Nov 01
TA  - MD Conference Express
PG  - 15--15
VI  - 8
IP  - 3
4099  - http://mdc.sagepub.com/content/8/3/15.1.short
4100  - http://mdc.sagepub.com/content/8/3/15.1.full
AB  - Over 50% of schizophrenia patients drop out of controlled trials within 6 months due to lack of efficacy or in some cases tolerability issues [Liu-Siefert et al. BMC Med 2005; Lieberman JA et al. N Engl J Med 2005], particularly extrapyramidal symptoms (EPS), akathisia, weight gain, metabolic effects, sedation, and anticholinergic effects. EPS and akathisia effects carry an increased risk of suicide [Dong JY et al. J Affect Disord 2005] and poor adherence, while metabolic effects can increase the risk for diabetes and cardiovascular disease. Iloperidone, a mixed D2/5-HT2 antagonist that is under US Federal Drug Administration (FDA) review, may provide a lower EPS/akathisia liability.